Current Status
Not Enrolled
Price
Free
Get Started

Newborn Screening and LSDs in the Neonatal Period

To obtain CME/CE credit, you must LOG-IN and ENROLL (click orange button at top of page)

Lysosomal & Rare Disorders Research & Treatment Center

GRIDS-2023

Newborn Screening and LDs in the Neonatal Period

January 30, 2024 – January 30, 2025

Estimated time to complete: 1.75 hours

Continuing Education Information

This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.

Speakers

Can Ficicioglu, MD, PhD
Children’s Hospital of Philadelphia, Philadelphia, PA

Orna Staretz-Chacham, MD
Soroka University Medical Center, Beer-Sheva, Israel

Debra Regier, MD
Children’s National, Washington DC

David Kronn, MD
New York Medical College, Valhalla, NY

Disclosures

AffinityCE staff, LDRTC staff, CheckRare CE staff, planners, and reviewers, have no relevant financial interests to disclose. All faculty disclosures are listed below and will be stated prior to the start of each session.

Faculty disclosures

Can Ficicioglu, MD, PhD
Advisor/Consultant: Horizon Therapeutics, Travere, Sanofi Genzyme, Takeda, Avrobio, Acer and Chiesi.
Research grants: Travere, Passage Bio, Regenxbio, Sanofi Genzyme, Takeda, JNANA, Synlogic, Denali and JCR.

Orna Staretz-Chacham, MD
No disclosures

Debra Regier, MD
Educational grant: Takeda, Travere.

David Kronn, MD
Advisory Board: AskBio
Research grant: Sanofi
Speaker’s bureau: Sanofi

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships reported have been mitigated prior to the commencement of the activity through peer review of content by non-conflicted reviewers.

Learning Objectives

At the end of this activity, participants should be able to address one or more of the following:

  • Describe how a disease get on newborn screening panels
  • Describe best practices to add diseases to newborn screening panels
  • Describe best practices to interpret newborn screening results

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 1.75 hours of continuing nursing education credit.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Genetic Counselors
Category 2 CEU

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.

Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Commercial Support

Educational grant support for GRIDS 2023 provided by Amicus, Chiesi, Sanofi, Lilly, and Takeda.

Participation Costs

There is no cost to participate in this activity.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.
Send customer support requests to cds_support+ldrtc@affinityced.com.

Course Content